SUNDAY, JULY 15, 2018

Emergent BioSolutions closes on acquisition of Bracco Diagnostics division

Emergent BioSolutions, Inc., a Rockville, Maryland-based specialty pharmaceutical company, announced on Friday that it closed on its acquisition of the Healthcare Protective Products Division of Bracco Diagnostics, Inc.

The agreement with Bracco, a Monroe Township, N.J.-based company, includes the RSDL decontamination lotion product that is cleared for marketing by the U.S. Food and Drug Administration to remove or neutralize chemical warfare agents from the skin. Emergent said the acquisition of the product would diversify Emergent's biodefense franchise into the market of chemical countermeasures.

"As a result of this transaction closing, Emergent is focused on the uninterrupted supply of RSDL product to customers and on the seamless integration of the new Healthcare Protective Products Group into our biodefense division," Adam Havey, the executive vice president and president of Emergent's biodefense division, said.

The U.S. Department of the Army and the Canadian Department of National Defence both played a significant part in the development and licensing of RSDL. RSDL was also cleared for sale by Australia's Therapeutics Goods Administration, the U.K. Medicines and Healthcare Products Regulatory Agency and Health Canada.

"This news, which comes on the heels of other positive developments in our biodefense division, including receiving BioThrax market authorization in Germany as well as reporting positive data from our pivotal study supporting licensure of a post-exposure prophylaxis indication for BioThrax, reinforces Emergent's leadership position in the biodefense arena," Havey said.